- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05397613
STAIR for Trauma and Emotion Dysregulation
25 de maio de 2022 atualizado por: Sanno Zack, Stanford University
Examining the Effectiveness of STAIR as an Alternative to DBT for Patients With Emotion Dysregulation and PTSD
This study will examine the impact of Skills Training in Affective and Interpersonal Regulation (STAIR) group, using self-report measures, on Posttraumatic Stress Disorder (PTSD), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care.
Aims include assessing the feasibility of STAIR, reducing patients' trauma and emotion dysregulation symptoms, examining whether STAIR may be used as an alternative to DBT for patients on the DBT, and improving patient satisfaction and clinic efficiency
Visão geral do estudo
Status
Inscrevendo-se por convite
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Antecipado)
30
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Be 18 years or older.
- Have a DSM-5 diagnosis and/or symptoms for which DBT is an indicated treatment
- Meet DSM-5 criteria for a diagnosis of posttraumatic stress disorder (PTSD)
- Meet criteria at a subclinical level for BPD (a minimum of three symptoms)
- Must be able to make group commitments for attendance, safety, and sobriety during group
Exclusion Criteria:
- If currently receiving individual therapy that follows the DBT protocol or is an evidence-based trauma-focused therapy
- If the STAIR therapy group is determined to be clinically contraindicated
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: STAIR
Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
|
Experimental: Waitlist control
First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures.
Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants who complete the STAIR intervention
Prazo: Week 12
|
This number will include those who attend the 12 weeks of STAIR with no more than three missed sessions
|
Week 12
|
|
Total score of patient treatment satisfaction ratings
Prazo: Week 12
|
Calculate the total score for each participant on the Client Satisfaction Questionnaire-8, and find the average of those scores.
Scores are summed across items.
Items 2, 4, 5, and 8 are reverse scored.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
Week 12
|
|
Frequency of participant attendance
Prazo: Week 1 through Week 12
|
Calculate the number of patients who attended each week of the STAIR treatment.
|
Week 1 through Week 12
|
|
Change in emotion regulation total score from baseline to Week 12
Prazo: Baseline to Week 12
|
Problems with emotion regulation will be assessed using the Difficulty in Emotion Regulation Scale.
Total score ranges from 36 to 180.
Higher scores indicate greater problems with emotion regulation.
|
Baseline to Week 12
|
|
Change in the severity of posttraumatic stress disorder symptom total score from baseline to Week 12
Prazo: Baseline to Week 12
|
The severity of posttraumatic stress disorder symptoms is measured using the PCL-5.
Items are rated using a 5-point likert scale ranging from 0 "not at all" to 4 "extremely."
All 20 items are summed to obtain a total score (0 to 80), higher scores indicate higher severity of PTSD symptoms.
|
Baseline to Week 12
|
|
Change in Borderline symptom severity total score from baseline to Week 12
Prazo: Baseline and Week 12
|
Using the Borderline Evaluation of Severity Scale comprising of 15 items using a likert scale rated from 5 "Almost Always" to 1 "Almost Never."
There are three subscales that comprise this measure: (1) Thoughts and Emotions (2) Behaviors-Negative and (3) Behaviors-Positive.
The total for each subscale is determined to score the BEST.
The scores of subscales A and B are then added together and the total from subscale C is subtracted.
A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).
|
Baseline and Week 12
|
|
Change in Borderline Symptom List-23 total score from baseline to Week 12
Prazo: Baseline and Week 12
|
This measure assesses feelings and experiences commonly endorsed by patients with BPD.
The 23-item scale utilizes a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very strong."
The BSL-23 is scored by summing up the scores for all of the items.
Total score ranges from 0 to 92, with higher scores reflecting more severe borderline personality symptoms.
|
Baseline and Week 12
|
|
Change in current symptoms of psychopathology and psychological distress total score from baseline to Week 12
Prazo: Baseline and Week 12
|
The Symptom Checklist-90-Revised is a 90-item multidimensional self-report symptom measure that assesses current symptoms of psychopathology and psychological distress.
The items were scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely).
It assesses nine symptom dimensions (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism).
Global measures are provided to summarize overall distress, and these include the Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total.
Raw scores are calculated by dividing the sum of scores for a specific dimension by the number of items in the dimension.
Global severity index is calculated by summing the scores of the nine dimensions and additional items, then dividing by the total number of responses.
Total score ranges from 0 to 360.
Higher scores indicate worsening of disease.
|
Baseline and Week 12
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Sanno Zack, PhD, Stanford Universtiy
- Investigador principal: Emily Livermore, PsyD, Stanford University
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Antecipado)
15 de junho de 2022
Conclusão Primária (Antecipado)
15 de junho de 2025
Conclusão do estudo (Antecipado)
15 de junho de 2025
Datas de inscrição no estudo
Enviado pela primeira vez
24 de maio de 2022
Enviado pela primeira vez que atendeu aos critérios de CQ
25 de maio de 2022
Primeira postagem (Real)
31 de maio de 2022
Atualizações de registro de estudo
Última Atualização Postada (Real)
31 de maio de 2022
Última atualização enviada que atendeu aos critérios de controle de qualidade
25 de maio de 2022
Última verificação
1 de maio de 2022
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 64219
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .